http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2757874-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 |
| filingDate | 2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a1358fb7e582c0173d95c2956b6cab8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b26c135b93fd5078b4db5fa115175e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8efb76d94f0a103bc8c047b838c1fba3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c7cd40fcb43076ca6ac6ce01e802749 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbb82b0cc5bb644872e1f8671896d8a8 |
| publicationDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2757874-C1 |
| titleOfInvention | Drug with complex pharmacological effect for the treatment of cardiovascular diseases, correction of cerebral circulation disorders, treatment of consequences of cerebrovascular diseases (options) |
| abstract | FIELD: pharmacology.SUBSTANCE: invention relates to pharmacology and concerns the use ofmeso- andracemicforms of 2,6-di(1,7,7-trimethylbicyclo[2.2.1]heptane-exo-2-yl)-4-methylphenol as drugs for the treatment of cardiovascular diseases, correction of cerebral circulation disorders, treatment of consequences of cerebrovascular diseases. Themeso-form is 2-{(1S, 2R, 4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-6-{(1R, 2S, 4S)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-4-methylphenol, theracemicform is 2,6-di{(1S,2R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-4-methylphenol and 2,6-di{(1R,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl}-4-methylphenol.EFFECT: technical result is expanding the arsenal of drugs for the treatment of cardiovascular diseases, correction of cerebral circulation disorders, treatment of consequences of cerebrovascular diseases, as well as enhancing pharmacological activity due to the stereospecific effect of isomers and due to the presence of a complex of pharmacological properties (antiradical, hemorheological, antiplatelet, antithrombogenic and neuroprotective activity, increase in cerebral blood flow), which also provides an increase in the effectiveness of treatment of the specified diseases.2 cl, 7 tbl, 7 ex |
| priorityDate | 2019-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 254.